Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 1998

View Archived Issues

Therapeutic Antibodies updates pipeline

Company Profile: PPL Therapeutics

Elan updates nicotine patch studies and its late-stage development pipeline

VIMRx and Columbia terminate research agreements

Pfizer: analysts' meeting highlights

Potent antifungal triazoles reported by Sankyo

Astra claims novel NOS inhibitors for asthma, rheumatoid arthritis and pain

Central muscarinic receptor agonists patented by U. of Toledo

Phase II clinical trial demonstrates ALX1-11 effective in treating osteoporosis

Novel compounds from P&G behave as alpha2-adrenoceptor agonists

Japanese lab prepares new, broad-spectrum carbapenems

Biomira initiates pivotal phase III trial of Theratope vaccine

StressGen's protein fusion vaccines elicit potent immune response without additional adjuvants

CuraGen, Glaxo Wellcome initiate collaborative pharmacogenomics-based drug discovery effort

Patent covering cytokine trap technology issued to Regeneron

Isis patents antisense oligonucleotides for cancer treatment

FDA approves Sandostatin LAR once-monthly depot formulation

PSC-833 plus chemotherapy is safe and effective in older patients with AML

Safer and more effective SERM compounds reported in development at Signal

Photogen initiates development of ocular disease Rx; receives U.S. patents for technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...